The Penn Center of Innovation was recognized in an article in Clinical Leader about how academic medical centers can leverage their unique advantages to develop and deliver cell and gene therapies. The article includes PCI Managing Director John Swartley’s, PhD, MBA, words about commercialization, noting: “technology transfer is more than just supporting the transaction, it is also about making the connections and building the network.”
The development of CAR T cell therapy and successful spin out of cell and gene therapy companies at Penn are also mentioned in the article as key examples of academic medical centers playing a key role in the discovery of novel therapies for unmet medical demands such as cell and gene therapies (CGTs).
Read the article here.